Physician profile
William Ellison
NPI 1548338197
$5,163.30
in general payments reported to CMS, 2019-2025
52 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,198 · 2020: $546 · 2021: $711 · 2022: $824 · 2023: $801 · 2024: $626 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $788.25 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Esperion Therapeutics, INC. | $524.41 | 2020-2022 | |
| Lilly USA, LLC | $325.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $309.29 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $296.86 | 2022-2025 | |
| Amgen INC. | $255.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $241.83 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $236.81 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $204.76 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.22 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $163.97 | 2019 | |
| Amarin Pharma, INC. | $162.29 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $132.95 | 2019-2023 | Spravato |
| Dexcom, INC. | $124.59 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.31 | 2019-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $110.16 | 2019-2023 | |
| Glaxosmithkline, LLC. | $94.65 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $90.38 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $89.84 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $84.29 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $58.00 | 2023 | Gvoke Hypopen, Keveyis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.77 | 2019 | |
| Eisai INC. | $50.15 | 2021-2024 | |
| Genentech USA, INC. | $44.91 | 2019-2021 | |
| Exact Sciences Corporation | $44.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $40.19 | 2024-2025 | Veozah |
| Boston Scientific Corporation | $27.34 | 2020-2025 | Bodyguardian |
| Tolmar, INC. | $25.21 | 2024 | |
| Axsome Therapeutics, INC. | $24.59 | 2023 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $23.59 | 2020 | |
| Radius Health, INC. | $22.46 | 2019 | |
| Daiichi Sankyo INC. | $18.50 | 2022 | |
| Abiomed | $18.46 | 2024 | Impella |
| Sumitomo Pharma America, INC. | $18.15 | 2023 | Gemtesa |
| Edwards Lifesciences Corporation | $17.81 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Inari Medical, INC. | $17.63 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Idorsia Pharmaceuticals US INC | $16.14 | 2024 | Quviviq |
| Cvrx, INC. | $15.88 | 2022 | |
| Inspire Medical Systems, INC. | $15.79 | 2025 | Inspire |
| Antares Pharma, INC. | $15.43 | 2024 | Xyosted |
| Mylan Specialty L.P. | $15.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.95 | 2023 | Camzyos |
| Insmed, INC. | $13.63 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.30 | 2019 | |
| Phathom Pharmaceuticals, INC. | $11.71 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $11.63 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.